A study by South African scientists into the new coronavirus variant driving a resurgence of new cases in the country raises concern about the efficacy of vaccines and a new class of therapies.
Half the blood samples taken from a group of people to have recovered from Covid-19 didn’t have the antibodies needed to protect against the 501Y.V2 strain identified last month, according to the paper by South Africa’s National Institute for Communicable Diseases. In the other half, antibody levels were reduced and the risk of re-infection couldn’t be determined, according to the institute.
New strains of the virus have also been identified in countries including the UK and Brazil, leading to concerns that increasingly dangerous versions of the pathogen still yet to emerge may hamper the global roll out of vaccines.
The NICD findings may “foreshadow reduced efficacy of current spike-based vaccines,” the scientists said. They also suggest that treatment with plasma from donors who’ve had the coronavirus may not be successful in those with this variant.
The strain that emerged in South Africa is about 50% more transmissible than earlier versions, Salim Abdool Karim, co-chair of the Covid-19 ministerial advisory committee, said in a presentation earlier this week. However, there’s no evidence it’s more likely to cause hospitalisation or death, he said.
A separate study by Pfizer Inc. and BioNTech SE showed that their Covid-19 vaccine will protect against the new variant of the coronavirus that emerged in the UK Scientists have previously said many existing vaccines could be adapted to new strains if needed.
© 2021 Bloomberg
Credit: Source link
